Document Detail


Upper extremity deep venous thrombosis.
MedLine Citation:
PMID:  11885029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Upper extremity deep venous thrombosis (UEDVT) makes up approximately 1-4% of all episodes of deep venous thrombosis (DVT). Risk factors for UEDVT include central venous catheterization, strenuous upper extremity exercise or anatomic abnormalities causing venous compression, inherited thrombophilia, and acquired hypercoagulable states including pregnancy, oral contraceptive use, and cancer. Unexplained or recurrent UEDVT should prompt a search for inherited hypercoagulable states or underlying malignancy. Clinical presentations include arm, neck, and shoulder pain; edema; skin discoloration; tenderness; and venous distension. Because UEDVT is frequently asymptomatic until complications ensue, a high index of suspicion is required for patients with one or more risk factors for thrombosis. Pulmonary embolism and post-thrombotic syndrome are the most common sequelae of UEDVT. Early detection and treatment of UEDVT decrease complications, morbidity, and mortality. Compressive ultrasonography is an effective and economical means of confirming the clinical diagnosis in most patients. Traditional anticoagulant therapy of UEDVT is giving way to a multimodal approach involving transcatheter thrombolytic therapy followed by a minimum of 3 months of warfarin sodium anticoagulant therapy, venous decompression as needed, and balloon angioplasty with stenting for treatment of residual stricture. Low-dose anticoagulant therapy can safely and effectively mitigate the increased risk of UEDVT associated with the use of central venous catheters.
Authors:
Aruna Kommareddy; Michael H Zaroukian; Houria I Hassouna
Related Documents :
25175609 - Air pollution exposure and health effects in fetus.
10625209 - Detection of decreased response to activated protein c during pregnancy by an endogenou...
25225209 - Increased levels of copeptin before clinical diagnosis of preelcampsia.
2546279 - Low molecular weight heparin novo (lhn-1) does not cross the placenta during the second...
19474699 - Risk factors for clinical manifestations in carriers of factor v leiden and prothrombin...
4615859 - Thromboembolic disorders in pregnancy: pathophysiology, diagnosis, and treatment, with ...
14617469 - Enthusiasm and teamwork--the basis for increase in laparoscopic surgery for ectopic pre...
17344509 - Maternal vitamin d intake during pregnancy and early childhood wheezing.
2437799 - Declining serum concentrations of the beta-subunit of human chorionic gonadotropin and ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  28     ISSN:  0094-6176     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-03-08     Completed Date:  2002-09-13     Revised Date:  2006-03-07    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  89-99     Citation Subset:  IM    
Affiliation:
Department of Medicine, Michigan State University, East Lansing, Michigan 48824-1313, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arm / blood supply*,  physiopathology*
Catheterization / adverse effects
Humans
Risk Factors
Thoracic Outlet Syndrome / etiology,  physiopathology
Thrombophilia / complications,  etiology
Venous Thrombosis* / complications,  diagnosis,  etiology,  therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence.
Next Document:  A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X s...